natgillin/translations-raw huggingface dataset:
Patients being treated with Zoledronic Acid Accord should not be treated with Aclasta or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown. 
Bolesnici koji se liječe Zoledronatnom kiselinom Accord ne smiju istodobno uzimati Aclastu ili bilo koji drugi bisfosfonat, budući da nisu poznati kombinirani učinci tih lijekova.
• To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Accord concentrate (5ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. 
• Da biste pripremili otopinu za infuziju koja sadrži 4 mg zoledronatne kiseline, dodatno razrijedite koncentrat Zoledronatne kiseline Accord (5 ml) sa 100 ml otopine za infuziju koja ne sadrži kalcij niti druge dvovalentne katione.
Caution is advised when zoledronic acid is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products. 
Savjetuje se oprez prilikom primjene zoledronatne kiseline sa antiangiogenim lijekovima budući da je zabilježena incidencija osteonekroze čeljusti u bolesnika istovremeno liječenih ovim lijekovima.
In the clinical trials, renal deterioration was defined as follows: For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l; For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 µmol/l), an increase of 1.0 mg/dl or 88 µmol/l. 
U kliničkim je ispitivanjima pogoršanje funkcije bubrega bilo definirano na sljedeći način: povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 μmol/l, u bolesnika s normalnom početnom vrijednošću kreatinina u serumu (< 1,4 mg/dl ili < 124 μmol/l), povišenje vrijednosti kreatinina za 1,0 mg/dl ili 88 μmol/l, u bolesnika s poremećenom početnom vrijednošću kreatinina (> 1,4 mg/dl ili > 124 μmol/l).
The pain score for zoledronic acid was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score. 
Rezultat na ljestvici bola za zoledronatnu kiselinu bio je dosljedno ispod početne razine, a smanjenje bola bilo je praćeno trendom smanjenja bodova za analgetike.
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid: 
Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja zoledronatnom kiselinom u dozi od 4 mg:
To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. 
Da bi se procijenili učinci zoledronatne kiseline u dozi od 4 mg u usporedbi s 90 mg pamidronata, u unaprijed planiranoj analizi kombinirali su se rezultati dva glavna multicentrična ispitivanja u bolesnika s hiperkalcemijom izazvanom tumorom.
During post-marketing experience the following reactions have been reported (frequency rare): Atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction). 
U razdoblju nakon stavljanja lijeka u promet zabilježene su sljedeće reakcije (rijetke učestalosti): atipični suptrohanterični prijelomi i prijelomi dijafize bedrene kosti (nuspojava skupine bisfosfonata).
In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days). 
zimice i bolova u kostima, zglobovima i/ili mišićima; u većini slučajeva nije potrebno posebno liječenje, i simptomi nestaju nakon kratkog vremena (nekoliko sati ili dana).
* Includes vertebral and non-vertebral fractures ** Accounts for all skeletal events, the total number as well as time to each event during the trial NR-Not Reached 
** Odnosi se na sve koštane događaje, njihov ukupni broj i vrijeme do svakog pojedinog događaja tijekom ispitivanja.
In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2-2.5 mg. 
U ispitivanjima faze I, određivanja doze u bolesnika s blagom do umjerenom hiperkalcemijom izazvanom tumorom, djelotvorne ispitivane doze kretale su se u rasponu od približno 1,2 do 2,5 mg.
Blurred vision, scleritis and orbital inflammation 
zamagljen vid, skleritis i upala orbite
Proportion of patients with SREs (%) p-value 
Udio bolesnika s koštanim događajem (%) p-vrijednost Medijan
Patients must be maintained well hydrated prior to and following administration of zoledronic acid. 
Bolesnici moraju biti dobro hidrirani prije i nakon primjene zoledronatne kiseline.
In a pooled analysis of safety data from zoledronic acid registration trials for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to zoledronic acid (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%). 
U analizi objedinjenih podataka o sigurnosti primjene zoledronatne kiseline iz registracijskih ispitivanja za sprječavanje koštanih događaja u bolesnika s uznapredovalom zloćudnom bolešću koja je zahvatila kosti, sumnjalo se da je učestalost nuspojave oštećenja funkcije bubrega povezana sa zoledronatnom kiselinom (nuspojava) na sljedeći način: multipli mijelom (3,2%), karcinom prostate (3,1%), karcinom dojke (4,3%), karcinom pluća i drugi solidni tumori (3,2%).
Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4). 
Slučajevi osteonekroze čeljusti pretežno su zabilježeni u onkoloških bolesnika liječenih lijekovima koji inhibiraju resorpciju kosti, kao što je zoledronatna kiselina (vidjeti dio 4.4).
Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria 
astenija, periferni edemi, reakcije na mjestu primjene injekcije (uključujući bol, iritaciju, oteklinu i otvrdnuće), bol u prsištu, povećanje tjelesne težine, anafilaktična reakcija/šok, urtikarija
• Skin reactions (redness and swelling) at the infusion site, rash, itching. 
• kožne reakcije (crvenilo i oticanje) na mjestu primjene infuzije, osip, svrbež
Zoledronic acid is contraindicated in breast-feeding women (see section 4.3). 
Zoledronatna kiselina kontraindicirana je tijekom dojenja (vidjeti dio 4.3).
• As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia). 
• kao posljedica niskih razina kalcija: nepravilni otkucaji srca (srčana aritmija, uslijed hipokalcemije).
Do not receive Zoledronic Acid Accord: 
Ne smijete primati Zoledronatnu kiselinu Accord:
In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. 
U randomiziranom, dvostruko slijepom, kontroliranom ispitivanju u trajanju od 3 godine u kojem se ocjenjivala djelotvornost i sigurnost zoledronatne kiseline u dozi od 5 mg jedanput godišnje u usporedbi s placebom u liječenju postmenopauzalne osteoporoze (PMO), ukupna incidencija atrijske fibrilacije iznosila je 2,5% (96 od 3862) u bolesnica koje su primale zoledronatnu kiselinu u dozi od 5 mg i 1,9% (75 od 3852) u onih koje su primale placebo.
• The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line. 
• Otopina koja sadrži zoledronatnu kiselinu daje se kao jednokratna 15-minutna intravenska infuzija u zasebnoj infuzijskoj liniji.
• Keep Zoledronic Acid Accord out of the reach and sight of children. 
Zoledronatnu kiselinu Accord čuvajte izvan dohvata i pogleda djece.
• Urticaria. 
• koprivnjača.
Table 5: Proportion of complete responders by day in the combined TIH studies 
Tablica 5: Udio ispitanika s potpunim odgovorom prema danima u kombiniranim ispitivanjima liječenja hiperkalcemije izazvane tumorom
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
Ako imate bilo kakvih dodatnih pitanja o uporabi ovog lijeka, obratite se svom liječniku, ljekarniku ili medicinskoj sestri.
• Zoledronic Acid Accord is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line. 
• Zoledronatna kiselina Accord daje se u venu kao infuzija (drip) u trajanju od najmanje 15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
What you need to know before you are given Zoledronic Acid Accord 3. 
Što morate znati prije nego primite Zoledronatnu kiselinu Accord 3.
Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth 
proljev, zatvor, bolovi u trbuhu, dispepsija, stomatitis, suha usta
A subset had recurrence of symptoms when rechallenged with zoledronic acid or another bisphosphonate. 
U dijela tih bolesnika simptomi su se vratili nakon ponovnog izlaganja zoledronatnoj kiselini ili drugom bisfosfonatu.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient-skeletal morbidity rate. 
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku - stopu koštanog pobola.
In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section “Posology” above and section 4.4). 
U bolesnika s blagim do umjerenim oštećenjem funkcije bubrega preporučuju se snižene doze zoledronatne kiseline (vidjeti dio “Doziranje” iznad i dio 4.4).
Mannitol (E421) Sodium citrate Water for injections 
6.1 Popis pomoćnih tvari manitol (E421) natrijev citrat voda za injekcije
What you need to know before you are given Zoledronic Acid Accord 
Što morate znati prije nego primite Zoledronatnu kiselinu Accord
Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid. 
Bolesnicima treba provjeriti razinu kreatinina u serumu prije svake primjene doze zoledronatne kiseline.
There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid. 
Pronašla se brža normalizacija korigiranog kalcija u serumu 4. dana kod doze zoledronatne kiseline u dozi od 8 mg i 7. dana kod doze zoledronatne kiseline u dozi od 4 mg i 8 mg.
What Zoledronic Acid Accord is and what it is used for 2. 
Što je Zoledronatna kiselina Accord i za što se koristi 2.
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po bočici, tj. zanemarive količine natrija.
In the zoledronic acid-treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1). 
Brief Pain Inventory - BPI) nakon 4 tjedna i pri svakom sljedećem mjerenju tijekom ispitivanja u usporedbi s placebom (slika 1).
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid and other bisphosphonates as well as use of other nephrotoxic medicinal products. 
Čimbenici koji mogu povećati mogućnost pogoršanja funkcije bubrega uključuju dehidraciju, postojeće oštećenje funkcije bubrega, višestruke cikluse liječenja zoledronatnom kiselinom i drugim bisfosfonatima, kao i uzimanje drugih nefrotoksičnih lijekova.
Hypomagnesaemia, hypokalaemia 
hipomagnezemija, hipokalemija
• Flu-like symptoms including arthritis and joint swelling. 
• Simptomi nalik gripi uključujući artritis i oticanje zglobova.
Treatment of adult patients with tumour-induced hypercalcaemia (TIH). 
Liječenje odraslih bolesnika s hiperkalcemijom izazvanom tumorom.
Instructions for preparing reduced doses of Zoledronic Acid Accord: Withdraw the appropriate volume of the liquid concentrate, as follows: o 4.4 ml for 3.5 mg dose o 4.1 ml for 3.3 mg dose o 3.8 ml for 3.0 mg dose 
Izvucite sljedeći odgovarajući volumen tekućeg koncentrata: o 4,4 ml za dozu od 3,5 mg o 4,1 ml za dozu od 3,3 mg o 3,8 ml za dozu od 3,0 mg
• High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhoea constipation, 
• visok krvni tlak, nedostatak zraka, omaglica, tjeskoba, poremećaji spavanja, promjena osjeta okusa, drhtavica, trnci ili utrnulost šaka ili stopala, proljev, zatvor, bol u trbuhu, suha usta.
Pruritus, rash (including erythematous and macular rash), increased sweating 
svrbež, osip (uključujući eritematozni i makularni osip), pojačano znojenje
Do not mix Zoledronic Acid Accord concentrate with calcium-containing or other divalent cation-containing solutions such as lactated Ringer's solution. 
Nemojte miješati koncentrat Zoledronatne kiseline Accord s otopinama koje sadrže kalcij ili druge dvovalentne katione kao što je otopina Ringerovog laktata.
For storage conditions of the reconstituted solution for infusion, see section 6.3. 
Uvjete čuvanja razrijeđene otopine za infuziju vidjeti u dijelu 6.3.
What Zoledronic Acid Accord is and what it is used for 
Što je Zoledronatna kiselina Accord i za što se koristi
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. 
Čimbenici koji mogu povećati mogućnost propadanja funkcije bubrega uključuju dehidraciju, postojeće oštećenje funkcije bubrega, višestruke cikluse primanja zoledronatne kiseline ili drugih bisfosfonata, kao i istovremenu primjenu nefrotoksičnih lijekova ili kraće trajanje infuzije od trenutno preporučenog.
Anaemia 
anemija
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic Acid Accord. 
Tijekom liječenja Zoledronatnom kiselinom Accord sve bolesnike se mora poticati da održavaju dobru oralnu higijenu, redovito odlaze na stomatološke kontrole i odmah prijave bilo koji oralni simptom kao što je pomičnost zuba, bol ili oticanje, ili ranice koje ne cijele ili iscjedak.
Patients must be assessed prior to administration of zoledronic acid to ensure that they are adequately hydrated. 
Bolesnici moraju biti pregledani prije primjene zoledronatne kiseline kako bi se potvrdilo da su ogovarajuće hidrirani.
• if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. 
• osjećate ili ste osjećali bol, oticanje ili utrnulost čeljusti, težinu u čeljusti ili klimanje zuba.
When initiating treatment with zoledronic acid in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. 
Kad se počinje liječenje zoledronatnom kiselinom u bolesnika s multiplim mijelomom ili solidnim tumorom koji je metastazirao u kosti, potrebno je odrediti vrijednosti kreatinina u serumu i klirens kreatinina.
MARKETING AUTHORISATION HOLDER Accord Healthcare S.L.U. 
Nositelj odobrenja za stavljanje u promet gotovog lijeka Accord Healthcare S.L.U.
• The usual single dose given is 4 mg zoledronic acid. 
• Obično se daje jednokratna doza od 4 mg zoledronatne kiseline.
The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 ± 33% of the creatinine clearance, which showed a mean of 84 ± 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. 
Bubrežni klirens zoledronatne kiseline korelirao je s klirensom kreatinina, s time da je bubrežni klirens predstavljao 75±33% klirensa kreatinina, koji je prosječno iznosio 84 ± 29 ml/min (raspon, od 22 do 143 ml/min) u 64 uključena onkološka bolesnika.
Your doctor will carry out blood tests before you start treatment with Zoledronic Acid Accord and will check your response to treatment at regular intervals. 
Prije nego što počnete primati Zoledronatnu kiselinu Accord, liječnik će Vam napraviti krvne pretrage i u redovitim vremenskim razmacima provjeravati Vaš odgovor na liječenje.
Patients treated with Zoledronic Acid Accord should be given the package leaflet and the patient reminder card. Posology 
Bolesnicima koji se liječe Zoledronatnom kiselinom Accord potrebno je dati Uputu o lijeku i karticu-podsjetnik za bolesnika.
In a third phase III randomised, double-blind trial, zoledronic acid 4 mg or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. 
U randomiziranom, dvostruko slijepom ispitivanju faze III uspoređivala se zoledronatna kiselina u dozi od 4 mg s pamidronatom u dozi od 90 mg svaka 3 do 4 tjedna u bolesnika s multiplim mijelomom ili karcinomom dojke i najmanje jednom koštanom lezijom.
In patients who show evidence of renal deterioration during treatment, zoledronic acid should be withheld. 
U bolesnika u kojih se pojave znakovi pogoršanja funkcije bubrega tijekom liječenja treba prekinuti primjenu zoledronatne kiseline.
Table 2: Efficacy results (prostate cancer patients receiving hormonal therapy) Any SRE (+TIH) 
Tablica 2: Rezultati djelotvornosti (bolesnici s karcinomom prostate koji primaju hormonsku terapiju) Bilo koji koštani događaj (+ hiperkalcemija izazvana tumorom)
Risk reduction of suffering from multiple events** (%) 
p-vrijednost Stopa koštanog pobola p-vrijednost Smanjenje rizika od višestrukih događaja** (%)
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. 
Fibrilacija atrija pojavila se kao ozbiljna nuspojava u 1,3% (51 od 3862) bolesnica koje su primale zoledronatnu kiselinu u dozi od 5 mg i 0,6% (22 od 3852) bolesnica koje su primale placebo.
Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia) 
srčana aritmija (uslijed hipokalcemije)
The results demonstrated that zoledronic acid 4 mg showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. 
Rezultati su pokazali podjednaku djelotvornost zoledronatne kiseline u dozi od 4 mg i pamidronata u dozi od 90 mg u sprječavanju koštanih događaja.
Table 3: Efficacy results (solid tumours other than breast or prostate cancer) Any SRE (+TIH) 
Tablica 3: Rezultati djelotvornosti (solidni tumori osim karcinoma dojke i prostate) Bilo koji koštani događaj (+ hiperkalcemija izazvana tumorom)
Efficacy results are provided in Table 4. 
Rezultati djelotvornosti prikazani su u tablici 4.
• Do not use Zoledronic Acid Accord after the expiry date stated on the pack. 
Zoledronatna kiselina Accord se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju.
Instructions for preparing reduced doses of Zoledronic Acid Accord Withdraw an appropriate volume of the concentrate needed, as follows: 4.4 ml for 3.5 mg dose 
Upute za pripremu sniženih doza Zoledronatne kiseline Accord Izvucite odgovarajući volumen potrebnog koncentrata na sljedeći način:
• As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia). 
• kao posljedica niskih vrijednosti kalcija: napadaji, utrnulost i tetanija (kao posljedica hipokalcemije).
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. 
Pogoršanje funkcije bubrega, koje napreduje do zatajenja bubrega i dijalize, zabilježeno je u bolesnika nakon početne doze ili jednokratne doze zoledronatne kiseline u dozi od 4 mg.
This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Ovaj lijek ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. 
Nepravilan rad srca (srčana aritmija), napadaji, grčevi i trzanje mišića (tetanija) zabilježeni su kao posljedica teške hipokalcemije.
• Conjunctivitis. 
• konjunktivitis.
N Proportion of patients with SREs p-value Median time to SRE (days) 
Udio bolesnika s koštanim događajem (%) p-vrijednost Medijan vremena do koštanog događaja (dani)
Efficacy results are provided in Table 3. 
Rezultati djelotvornosti prikazani su u tablici 3.
Zoledronic Acid Accord concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Koncentrat Zoledronatna kiselina Accord ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Warnings and precautions Talk to your doctor, pharmacist or nurse before you are given Zoledronic Acid Accord 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite Zoledronatnu kiselinu Accord, ako:
Efficacy results are provided in Table 2. 
Rezultati djelotvornosti prikazani su u tablici 2.
• Sleepiness. 
• pospanost.
Nasopharyngitis 
nazofaringitis
The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. 
Izvučena količina koncentrata mora se dodatno razrijediti u 100 ml sterilne 0,9%-tne m/V otopine za injekciju natrijevog klorida ili 5%-tne m/V otopine glukoze.
CLINICAL PARTICULARS 4.1 Therapeutic indications Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. 
Sprječavanje koštanih događaja (patološki prijelomi, kompresija kralježaka, zračenje ili kirurški zahvat na kosti ili hiperkalcemija izazvana tumorom) u odraslih bolesnika s uznapredovalom zloćudnom bolešću koja je zahvatila kosti.
To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride or 5% w/v glucose solution. 
Da biste izbjegli moguće inkompatibilnosti, otopina za infuziju koja se koristi za razrjeđenje mora biti 0,9%-tna m/V otopina natrijevog klorida ili 5%-tna m/V otopina glukoze.
Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing) 
vrućica, sindrom sličan gripi (uključujući umor, tresavicu, malaksalost i crvenilo uz osjećaj vrućine)
4.2 Posology and method of administration Zoledronic Acid Accord must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. 
Zoledronatnu kiselinu Accord bolesnicima smiju propisivati i primjenjivati samo zdravstveni djelatnici s iskustvom u intravenskoj primjeni bisfosfonata.